Home

MGC Pharma supplement offers COVID-19 treatment hope

Headshot of Matt Birney
Matt BirneySponsored
The pre-clinical in-vitro laboratory study points to the effectiveness of ArtemiC in response to inflammatory stimuli.
Camera IconThe pre-clinical in-vitro laboratory study points to the effectiveness of ArtemiC in response to inflammatory stimuli. Credit: File

ASX-listed bio-pharma company MGC Pharmaceuticals’ natural supplement “ArtemiC” may end up helping in the global fight against Coronavirus after results from pre-clinical in-vitro laboratory tests in Israel showed a response on human immune function thought to be favourable in the treatment of COVID-19.

According to MGC Pharma, the results from the pre-clinical in-vitro lab testing lend weight to the claim ArtemiC can modify the function of human immune cells in response to inflammatory stimuli. Some elements of the formulation demonstrate an effective response on immune function in a manner considered desirable in combating the virus.

These findings, it added, support the clinical study theory that ArtemiC can have a beneficial impact on the malignant “Cytokine Storm”, which is said to play an important role in the clinical deterioration of those patients severely affected by infection with the Coronavirus.

When the production of cytokines is excessive and uncontrolled it is described as a Cytokine Storm, which is brought on by the failure to contain the body’s reaction to stimuli that occur in response to infection.

Get in front of tomorrow's news for FREE

Journalism for the curious Australian across politics, business, culture and opinion.

READ NOW

The severe clinical deterioration due to COVID-19 is to a significant degree attributed to these circumstances of Cytokine Storm and serves as a representative example of the fatal consequences that such a failure may cause, the company explained.

Current clinical evidence in COVID-19 patients suggests the Cytokine Storm is an uncontrolled overproduction of soluble markers of inflammation which, in turn, lead to a systemic inflammatory response, and is a major factor responsible for the occurrence of Acute Respiratory Distress Syndrome – the main mortality reason in COVID-19 patients.

The in-vitro immunological evaluations were conducted by independent clinical research laboratory MyPlant Bio in Israel for MGC Pharma.

The pre-clinical study was designed to test the effect of ArtemiC and its ingredients – comprising Artemisinin, Curcumin, Boswellia serrata and Vitamin C – on responses of human immune cells to inflammatory stimuli.

Results indicate that ArtemiC can reduce the risk of inflammation. It’s early days and further studies are underway and planned to build on these initial findings to evaluate the preferable ratios between the active ingredients of ArtemiC.

We are very pleased to have achieved these results, which have been completed in line with FDA requirements for COVID-19 studies.

MGC Pharma Co-founder and Managing Director, Roby Zomer

NB: This article is for general financial markets news purposes only and is not to be taken as an endorsement of, or advertisement for any individual product, medicine, or drug.

Is your ASX listed company doing something interesting? Contact: matt.birney@wanews.com.au

Get the latest news from thewest.com.au in your inbox.

Sign up for our emails